Ixekizumab + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Axial Spondyloarthritis

Conditions

Axial Spondyloarthritis

Trial Timeline

Aug 2, 2016 → May 7, 2019

NCT ID

NCT02757352

About Ixekizumab + Placebo

Ixekizumab + Placebo is a phase 3 stage product being developed by Eli Lilly for Axial Spondyloarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02757352. Target conditions include Axial Spondyloarthritis.

What happened to similar drugs?

6 of 20 similar drugs in Axial Spondyloarthritis were approved

Approved (6) Terminated (1) Active (14)

✅AdalimumabAbbVieApproved

✅Secukinumab 150 milligram [Cosentyx]NovartisApproved

✅Secukinumab + Placebo + SecukinumabNovartisApproved

✅etanercept + etanercept + placeboPfizerApproved

✅Tofacitinib 5 MGPfizerApproved

✅Certolizumab PegolUCBApproved

🔄Brodalumab + PlaceboKyowa KirinPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04285229	Phase 3	Completed	Apr 10, 2020	Mar 17, 2022	Spondyloarthritis
NCT03364309	Phase 3	Completed	Apr 26, 2018	Jun 4, 2020	Plaque Psoriasis
NCT03129100	Phase 3	Completed	May 9, 2017	May 27, 2021	Axial Spondyloarthritis
NCT02757352	Phase 3	Completed	Aug 2, 2016	May 7, 2019	Axial Spondyloarthritis
NCT02696798	Phase 3	Completed	Apr 12, 2016	May 3, 2019	Spondyloarthritis
NCT02718898	Phase 3	Completed	Apr 1, 2016	Feb 21, 2018	Genital Psoriasis
NCT02584855	Phase 3	Completed	Sep 14, 2015	Oct 30, 2018	Psoriatic Arthritis
NCT02513550	Phase 3	Completed	Aug 1, 2015	Aug 3, 2017	Plaque Psoriasis
NCT01107457	Phase 2	Completed	Apr 1, 2010	Jul 1, 2016	Psoriasis

Competing Products

20 competing products in Axial Spondyloarthritis

See all competitors

Product	Company	Stage	Hype Score
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
Brodalumab + Placebo	Kyowa Kirin	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 3	36
SHR-1314	Jiangsu Hengrui Medicine	Phase 1	29
Upadacitinib	AbbVie	Pre-clinical	33
Adalimumab	AbbVie	Approved	35
Adalimumab + Placebo + Open-label Adalimumab	AbbVie	Phase 3	40
adalimumab + Placebo	AbbVie	Phase 3	40
Treatment	Merck	Pre-clinical	66
Golimumab	Merck	Phase 3	40
Tulisokibart + Placebo	Merck	Phase 2	42
Secukinumab 150 milligram [Cosentyx]	Novartis	Approved	39
secukinumab	Novartis	Pre-clinical	26
Secukinumab + Placebo	Novartis	Phase 3	40
Secukinumab + Placebo + Secukinumab	Novartis	Approved	47
Secukinumab + Secukinumab and Placebo	Novartis	Phase 3	40
Secukinumab/Adalimumab-Biosimilar	Novartis	Phase 3	40
Brodalumab 210 mg + Placebo	Amgen	Phase 2	27
Etanercept 25mg + Sulfasalazine	Pfizer	Phase 2	31